LawIntakerInjury information & intake
Active MDLPrescription drugs

Depo-Provera Meningioma Lawsuits and MDL 3140

Federal cases allege that repeated or long-term medroxyprogesterone acetate injections contributed to intracranial meningioma and that earlier warnings were inadequate. Defendants deny liability.

General information, not medical or legal advice. Do not change treatment because of a lawsuit page.

Federal proceedingMDL 3140
Pending actions5,830
JPML report dateJuly 1, 2026
Current status: Active MDLRapidly growing federal litigation with a current U.S. label warning addressing reported meningiomas.

Case snapshot

What this litigation is about

Product or exposure
Depo-Provera CI and alleged generic equivalents containing depot medroxyprogesterone acetate (DMPA).
Defendants commonly named
Pfizer entities and other product-specific manufacturers or sellers identified in an individual complaint.
Federal court
MDL 3140, Northern District of Florida

Injuries alleged in the litigation

  • Intracranial meningioma
  • Brain or spinal tumor treatment
  • Surgery, radiation, seizures, vision or neurologic injury

An allegation is not a medical conclusion or finding of liability. Product, diagnosis, timing and causation must be evaluated individually.

Medical and scientific evidence

What the current sources do—and do not—show

The 2024 BMJ national case-control study examined selected progestogens and intracranial meningioma surgery; it reported an association for prolonged use of injectable medroxyprogesterone acetate. Observational research can identify an association but cannot decide causation in one patient.

The current U.S. prescribing information says meningiomas have been reported after repeated administration, primarily with long-term use, and directs monitoring and discontinuation if a meningioma is diagnosed. A label warning is important safety evidence, not automatic proof of a product-liability claim.

A source can be important without answering every question. Regulatory agencies decide whether to approve, warn about, recall or restrict products under public-law standards. Medical researchers evaluate populations, biological mechanisms or clinical outcomes. Courts decide whether particular expert opinions and claims satisfy legal standards. Those functions overlap, but they are not interchangeable. A recall does not prove that every product failed; an adverse-event report does not establish causation; and a pending lawsuit is not a scientific finding.

For an individual review, the useful question is narrower: does the record verify the product or exposure, the specific injury, a plausible sequence in time and a scientific theory that can address alternative causes? That analysis may require treating physicians, retained experts, pathology, imaging, laboratory data, device examination or exposure reconstruction. LawIntaker summarizes public information but does not perform that expert work or diagnose a condition.

Court and litigation status

What MDL 3140 means

MDL 3140 coordinates federal cases in the Northern District of Florida. The court's public page identifies common questions about general causation, knowledge of risk, warnings, and alleged safer alternatives while also recording that defendants deny liability.

The July 1, 2026 JPML report listed 5,830 pending actions. That number measures cases in the federal MDL on that date; it is not the number of every exposed patient and does not predict any settlement.

Multidistrict litigation is a federal case-management procedure. The Judicial Panel on Multidistrict Litigation may transfer cases sharing common factual questions to one judge for coordinated discovery, motions and other pretrial work. Coordination can reduce duplication, but it does not automatically turn every plaintiff into a member of one class. Unless a case resolves or is dismissed, it may later be remanded to the transferor court for trial. Some claims proceed in state court and are not included in the federal count.

The 5,830 pending actions shown above come from the JPML report dated July 1, 2026. The number can change with new filings, transfers, dismissals, settlements and remands. It does not represent all exposed people, all represented claimants or a finding that the common allegations are true. Readers should follow the linked court reports rather than a search-result snippet for the current number.

Settlements, verdicts and reported outcomes

What can responsibly be said now

No court-approved global settlement is identified in the cited official sources. Lawsuit advertising that publishes an estimated case value is not a court result and is not used here.

Even a final verdict is one result on one record. It may be appealed, reduced or resolved confidentially. It is not a promise of compensation or a calculator for another case.

Evidence checklist

Records that can make a screening useful

Do not delay asking for help because the file is incomplete. Begin by writing down the product or exposure, approximate dates, diagnosis and the names of the providers, employers, pharmacies, hospitals or facilities that may have records. Preserve original packaging, devices, photographs and electronic account records when it is safe and lawful to do so. Do not alter a product, arrange an explant or interrupt medical care for evidence purposes.

  • Injection administration records and pharmacy claims
  • OB-GYN or clinic charts showing first and last use
  • MRI/CT reports, pathology and neurosurgery records
  • Work-loss, rehabilitation and treatment-expense records

Medical-record requests should include the parts that establish both diagnosis and timing: medication administration, operative notes, device stickers, pathology, imaging, specialist assessments, discharge records and later follow-up. Billing and insurance records can help locate treatment that a patient no longer remembers precisely. A short personal timeline can connect symptoms, diagnosis, treatment, work loss and caregiving, but it supplements rather than replaces contemporaneous records.

Confidential screening

Questions an attorney intake may ask

  1. Which contraceptive injection was used, and for how long?
  2. Was a meningioma diagnosed, monitored or treated?
  3. When were the last injection and diagnosis?
  4. Which providers can verify exposure and diagnosis?

These questions are a starting point, not eligibility rules. Law firms can use different criteria based on their investigation, the current court orders, state law, the quality of product identification and the injury. A person who does not match one advertisement may still need deadline advice, while a person who matches a short checklist is not guaranteed representation. Only a legal team reviewing the actual facts can decide whether to offer an agreement.

Lawsuit process

How an individual mass-tort case usually proceeds

After an intake, counsel may verify product and medical records, investigate jurisdiction and deadlines, compare the injury with current case criteria and obtain expert input. If a law firm accepts the matter, the written agreement should explain fees, expenses and who will handle the case. Filing may occur directly in an MDL, in another federal district for later transfer, or in state court. The correct path depends on personal jurisdiction, venue, parties and the case-management orders.

Coordinated discovery may examine product design, testing, regulatory communications, adverse-event information, marketing, warnings and company knowledge. Plaintiffs provide exposure and medical proof through records, questionnaires, authorizations, fact sheets or depositions. Courts may select representative cases for bellwether work. The results can help parties assess strengths and risks, but no bellwether automatically decides the other cases.

Cases can end through dismissal, settlement, trial, appeal or a claims process. Any settlement may require proof categories, releases, lien resolution and court or administrator review. Health insurers, Medicare, Medicaid, workers' compensation plans or providers may assert reimbursement rights. A gross settlement headline is not the same as the amount a claimant receives after allocations, liens, fees and expenses.

Deadlines and legal rights

Why waiting for a settlement announcement can be dangerous

The filing deadline may depend on the state, injury date, diagnosis, when a connection could reasonably have been discovered, where the product was used or purchased, and which defendant is sued. Some states have statutes of repose that can run from a defendant's act even when an injury appears later. Death claims, minor claims, government service, bankruptcy proceedings and settlement programs may have different rules.

A webpage cannot calculate that deadline. Starting an intake does not file a case or stop time. If the events may be old, say so at the beginning of the attorney conversation. Save rejection letters, prior representation agreements and notices from courts or claims administrators; they may contain information needed for an accurate deadline analysis.

Medical care comes first.

Do not stop a medicine, remove or discard a device, or change treatment because of litigation information. Speak with a licensed healthcare professional. For severe or rapidly worsening symptoms, call 911 or seek emergency care.

Frequently asked questions

Depo-Provera lawsuit FAQ

Is the Depo-Provera litigation a class action?

The federal proceeding identified here is multidistrict litigation, or MDL 3140. It coordinates related federal cases for pretrial work. Individual exposure, injury, causation, defenses and damages generally remain separate.

Does the pending case count prove Depo-Provera caused the alleged injuries?

No. The JPML count shows how many federal actions were pending in the coordinated docket on the report date. It is not a medical finding, liability ruling, claimant total or settlement forecast.

Do I need every medical record before asking for a review?

No. Begin with the product or exposure, diagnosis, approximate dates and provider names. A legal team can explain which records are most important and whether it will request them with authorization.

Can LawIntaker tell me what my case is worth?

No. Value depends on proof, diagnosis, treatment, permanency, jurisdiction, defenses, deadlines and litigation outcomes. No verdict, bellwether or advertised range guarantees another result.

Primary sources

Verify the evidence and court status

  1. MDLs by actions pending, July 1, 2026 U.S. Judicial Panel on Multidistrict Litigation · Court
  2. Depo-Provera Products Liability Litigation, MDL 3140 U.S. District Court, Northern District of Florida · Court
  3. Depo-Provera CI prescribing information U.S. Food and Drug Administration · Government
  4. Use of progestogens and the risk of intracranial meningioma BMJ · Science

Sources are selected for court status, regulatory action, medical background or peer-reviewed evidence. A citation does not mean the source endorses LawIntaker or any lawsuit allegation.